Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Central Nervous System Neoplasms 3Fatigue 2Breast Neoplasms 2Brain Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Radiation Injuries 1Ototoxicity 1Melanoma 1Gliosarcoma 1Glioblastoma 1Depression 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1

Interventions

Temozolomide 31Radiotherapy 25Magnetic Resonance Spectroscopy 17Radiation 13Surgical Procedures, Operative 12Specimen Handling 9Radiotherapy, Conformal 9Bevacizumab 9Immunoglobulin G 8Disulfides 8Carmustine 8Vorinostat 7Radiotherapy, Intensity-Modulated 7Erlotinib Hydrochloride 7Chemotherapy, Adjuvant 7temsirolimus 6cediranib 6Sirolimus 6motexafin gadolinium 5Sorafenib 5Nivolumab 5Cilengitide 5Carboplatin 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5tipifarnib 4Lapatinib 4Congresses as Topic 4veliparib 3Procarbazine 3O(6)-benzylguanine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Glioblastoma × Mental Status and Dementia Tests × Clear all
NCT00731731 2022-08-04

Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

National Cancer Institute (NCI)

Phase 1/2 Completed
125 enrolled 12 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡